| Identification | Back Directory | [Name]
DICHLOROTRICARBONYLRUTHENIUM (II) DIMER | [CAS]
22594-69-0 | [Synonyms]
CORM-2
Dichlorotricarbonylruthenium dimer
Tetrachlorohexacarbonyldiruthenium
Tricarbonyldichlororuthenium dimer
TRICARBONYLDICHLORORUTHENIUM(II) DIMER
DICHLOROTRICARBONYLRUTHENIUM (II) DIMER
TRICARBONYLDICHLORORUTHENATE (II) DIMER
ruthenium(II) tricarbonyl chloride dimer
Dichlorotricarbonylruthenium(II) dimer,98%
Dichlorotricarbonylruthenium(II)dimer,min.98%
Dichlorotricarbonylruthenium(II) dimer, min. 98% | [Molecular Formula]
C6Cl4O6Ru2 | [MDL Number]
MFCD00011528 | [MOL File]
22594-69-0.mol | [Molecular Weight]
512.01 |
| Chemical Properties | Back Directory | [Appearance]
Off-white to slightly yellow powder | [Melting point ]
208°C (dec.) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C | [solubility ]
Soluble in DMSO | [form ]
crystal | [color ]
off-white | [Water Solubility ]
Insoluble in water | [InChI]
1S/6CO.4ClH.2Ru/c6*1-2;;;;;;/h;;;;;;4*1H;;/q;;;;;;;;;;2*+2/p-4 | [InChIKey]
JYHHJVKGDCZCCL-UHFFFAOYSA-J | [SMILES]
[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].[C-]#[O+].Cl[Ru]Cl.Cl[Ru]Cl |
| Hazard Information | Back Directory | [Chemical Properties]
Off-white to slightly yellow powder | [Uses]
Tricarbonyldichlororuthenium(II) dimer is used to enhance the coagulation and attenuation of vulnerability to fibrinolysis, modify thrombus growth or disintegration, enhances fibrinogen as a substrate for thrombin, and regulation of ion transport by gasotransmitters. Also used for various pharmacological studies. It is used as a CO donor for reactive oxygen species mediated bacterial killing. | [reaction suitability]
core: ruthenium
reagent type: catalyst | [in vivo]
Tricarbonyldichlororuthenium(II) dimer (1-10 mg/kg; oral gavage; single dose) has a protective effect in a rat model of gastric mucosal injury induced by ischemia-reperfusion[3]. | Animal Model: | Acute I/R gastric lesions treated male Wistar rats (250-300 g)[3] | | Dosage: | 1, 5 or 10 mg/kg | | Administration: | Oral gavage (i.g.); single dose | | Result: | Significantly decreased the area of I/R gastric damage and significantly increased GBF at doses of 1 or 5 mg/kg.
Significantly increased mRNA expression of HMOX-1 but not HMOX-2 in gastric mucosa and significantly increased blood concentration at dose of 5 mg/kg.
Significantly increased gastric mucosal PGE2 content at dose of 5 mg/kg.
Significantly decreased mRNA expression of iNOS but not eNOS in gastric mucosa at dose of 5 mg/kg.
Significantly decreased 8-hydroxyguanozine (8-OHG) concentration in gastric mucosa at dose of 5 mg/kg.
Decreased the expression of pro- and anti-inflammatory markers' mRNA and proteins at dose of 5 mg/kg. |
|
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
20/21/22-36/37/38 | [Safety Statements ]
26-37/39 | [RIDADR ]
UN3466 | [WGK Germany ]
3
| [HazardClass ]
6.1 | [PackingGroup ]
III | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral
Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
|
| Company Name: |
Alfa Aesar
|
| Tel: |
400-6106006 |
| Website: |
http://chemicals.thermofisher.cn |
|